GLPwatch
Papers (9189)
Page 32 of 154, ranked by citation count.
- Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
- Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.
- GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A.
- Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis.
- Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
- Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease.
- Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.
- Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.
- Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice.
- Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- The effect of fatty diacid acylation of human PYY<sub>3-36</sub> on Y<sub>2</sub> receptor potency and half-life in minipigs.
- Neurobehavioral effects of liraglutide and sitagliptin in experimental models.
- Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats.
- Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
- Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
- DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
- Liraglutide-induced acute kidney injury.
- LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.
- Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
- The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
- Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.
- The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials.
- Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
- Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with Type 2 diabetes.
- Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway.
- Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
- Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
- Liraglutide ameliorates renal injury in streptozotocin‑induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor‑κB pathway.
- Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
- Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.
- GLP-1-based therapies: the dilemma of uncertainty.
- Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice.
- Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
- Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.
- The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts.
- Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.
- Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
- Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.
- Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.
- Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
- Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers.
- Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.
- Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
- Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression.
- Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
- MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
- Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.
- The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.
- Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice.
- Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia.
- Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
- Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).
- Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test.
- Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.
- The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-<i>α</i> Expression in Macrophages.
- Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
- Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
- Exendin-4 enhances the differentiation of Wharton's jelly mesenchymal stem cells into insulin-producing cells through activation of various β-cell markers.
- Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease.